Q-omics provides the consensus-scored IL9RP1 profile across patient tissues and cancer cell-line models. IL9RP1 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, IL9RP1 is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, IL9RP1 RNA expression shows 6,341 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, KIRC, and STAD as cancer lineages where IL9RP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL9RP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL9RP1 survival associations across molecular data types. IL9RP1 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL9RP1 RNA expression–survival associations across cancer types. High IL9RP1 expression shows unfavorable associations in ACC, BRCA, LUAD and UVM, but favorable associations in BLCA and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify ACC as the clearest survival context for IL9RP1 RNA expression.
This table summarizes IL9RP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for IL9RP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL9RP1 shows lower tumor expression in LUAD and higher tumor expression in KIRC. The KIRC box plot shows higher IL9RP1 RNA expression in tumor versus normal tissue (log2 FC = +0.011, t-test p = .013).
This table shows molecular features associated with IL9RP1 in patient tissues and cancer cell lines. In patient samples, IL9RP1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
